secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-040810
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma gets positive FDA feedback for Ropidoxuridine Phase 2; cash $6.8M
--------------------------------------------------------------------------------

- Positive FDA feedback in Type B PIND meeting for Ropidoxuridine; IND submission imminent to start Phase 2 trial for glioblastoma.
- Exclusive license from Georgetown University for predictive biomarker test for prostate cancer radiation therapy.
- Q3 2023 operating expenses (excl non-cash) $1.6M; cash, cash equivalents and marketable securities $6.8M at Sep 30, 2023.
- Expanded patent coverage on HDAC inhibitor platform; published manuscript on SP-2-225 immune response post-radiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315223040810/0001493152-23-040810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315223040810/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer